title: Darapladib for the treatment of cardiovascular disease.
abstract: Elevated levels of phospholipase A2 have been linked to atherosclerotic plaque progression, instability via promoting inflammation and subsequent acute coronary events. Epidemiological studies have demonstrated the correlation between elevated levels associated phospholipase A2 and cardiovascular events. Therefore, specific inhibition of lipoprotein-associated phospholipase A2 with darapladib has been tested as a therapeutic option for atherosclerosis. The aim of this profile is to review the physiologic aspects of lipoprotein-associated phospholipase A2 and to revisit the clinical evidence of darapladib as therapeutic option for atherosclerosis.
authors.affiliation: Department of Interventional Cardiology, Erasmus University Medical Centre, Thoraxcenter, s-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
authors.forename: Carlos M
authors.initials: CM
authors.lastname: Campos
authors.forename: Pannipa
authors.initials: P
authors.lastname: Suwannasom
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Koenig
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
authors.forename: Hector M
authors.initials: HM
authors.lastname: Garcia-Garcia
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000187:drug effects*; D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy*; D001547:Benzaldehydes / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D010091:Oximes / Q000627:therapeutic use*; D058226:Plaque, Atherosclerotic / Q000188:drug therapy*; D012306:Risk; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides
chemical_list: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D001547:Benzaldehydes; D010091:Oximes; C529040:darapladib; D001713:Biphenyl Compounds; D004048:Diethylamines; D011744:Pyrimidinones; D013440:Sulfides
keywords: atherosclerosis; darapladib; inflammation; phospholipase A2